NCT04024137

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study of ZSP1273 in Adults With Acute Uncomplicated Influenza A

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 172 (actual)
• Sponsor: Guangdong Raynovent Biotech Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the antiviral effect, as measured by the time to alleviation of influenza symptoms and viral titer in nasopharyngeal secretions in adults with acute uncomplicated influenza A following administration of ZSP1273.

Conditions

• Influenza A

Interventions

Type	Name	Description
DRUG	ZSP1273 200 mg	1 X 200-mg tablet taken orally
DRUG	Placebo	2 tablets taken orally
DRUG	ZSP1273-400 mg	2 X 200-mg tablet taken orally
DRUG	Placebo	1 tablet taken orally
DRUG	ZSP1273-600 mg	3 X 200-mg tablet taken orally
DRUG	Placebo	3 tablets taken orally
DRUG	Placebo	Subjects will receive matching placebo of ZSP1273

Timeline

• Start date: 2019-12-07
• Primary completion: 2020-05-18
• Completion: 2020-05-18
• First posted: 2019-07-18
• Last updated: 2020-06-04

Locations

26 sites across 1 country: China